WO2023021525A1 - A human amnion-chorion based wound dressing material and method thereof - Google Patents
A human amnion-chorion based wound dressing material and method thereof Download PDFInfo
- Publication number
- WO2023021525A1 WO2023021525A1 PCT/IN2022/050734 IN2022050734W WO2023021525A1 WO 2023021525 A1 WO2023021525 A1 WO 2023021525A1 IN 2022050734 W IN2022050734 W IN 2022050734W WO 2023021525 A1 WO2023021525 A1 WO 2023021525A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane
- placental
- phmb
- wound dressing
- dressing material
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims description 20
- 229920002413 Polyhexanide Polymers 0.000 claims abstract description 58
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 58
- 206010052428 Wound Diseases 0.000 claims abstract description 57
- 230000001684 chronic effect Effects 0.000 claims abstract description 11
- -1 polyhexamethylene Polymers 0.000 claims abstract description 6
- 210000004379 membrane Anatomy 0.000 claims description 52
- 239000012528 membrane Substances 0.000 claims description 52
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 50
- 210000005152 placental membrane Anatomy 0.000 claims description 25
- 230000000845 anti-microbial effect Effects 0.000 claims description 17
- 210000001136 chorion Anatomy 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- 230000000813 microbial effect Effects 0.000 claims description 7
- 210000005059 placental tissue Anatomy 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 230000003190 augmentative effect Effects 0.000 claims description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 5
- 230000003169 placental effect Effects 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 229920004943 Delrin® Polymers 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004775 Tyvek Substances 0.000 claims description 4
- 229920000690 Tyvek Polymers 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims description 2
- ZILVNHNSYBNLSZ-UHFFFAOYSA-N 2-(diaminomethylideneamino)guanidine Chemical group NC(N)=NNC(N)=N ZILVNHNSYBNLSZ-UHFFFAOYSA-N 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 239000012984 antibiotic solution Substances 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 229960003260 chlorhexidine Drugs 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229960001585 dicloxacillin Drugs 0.000 claims description 2
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 229960003704 framycetin Drugs 0.000 claims description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims description 2
- 229960003128 mupirocin Drugs 0.000 claims description 2
- 229930187697 mupirocin Natural products 0.000 claims description 2
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 229940009188 silver Drugs 0.000 claims description 2
- 238000003892 spreading Methods 0.000 claims description 2
- 230000007480 spreading Effects 0.000 claims description 2
- 239000008223 sterile water Substances 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 210000001691 amnion Anatomy 0.000 abstract description 20
- 230000029663 wound healing Effects 0.000 abstract description 11
- 230000001154 acute effect Effects 0.000 abstract description 2
- 239000010410 layer Substances 0.000 description 13
- 230000035876 healing Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000012552 review Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 3
- 229920002118 antimicrobial polymer Polymers 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000005470 impregnation Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 229920001046 Nanocellulose Polymers 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003214 anti-biofilm Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/206—Biguanides, e.g. chlorohexidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- a HUMAN AMNION-CHORION BASED WOUND DRESSING MATERIAL AND METHOD THEREOF FIELD OF THE INVENTION The present invention relates to the field of acute and chronic wound management and healing. More particularly, it relates to wound healing attributes of placental membrane allograft, dehydrated human amnion-chorion (dAmCh) membrane impregnated with the broad spectrum antimicrobial polymer, Polyhexamethylene Biguanide (PHMB). BACKGROUND OF THE INVENTION Placenta-derived membranes are widely used as cellular matrices in the treatment of chronic wounds (Hughes et al, 2016), being immunoprivileged they are ideal for allograft therapies.
- dAmCh dehydrated human amnion-chorion
- PHMB Polyhexamethylene Biguanide
- HA amnion membrane
- HACM composite amnion-chorion
- PHMB Polyhexamethylene Biguanide
- the cited references are different from the present inventions as (a) the developed product do not contain impregnated PHMB; (b) it is a multilayer, rigid construct which needs assembly of allograft, base sheet, and support layer into wound dressing; (c) it do not have an intact amnion-chorion membrane as they are separated by mechanical stripping; (d) the respective dressing is to be placed inside the boundaries of wound; and (e) it mentions about the application of processed viscous amniotic fluid to surgery site to enhance the healing.
- D5: IN2456/CHE/2015A discloses a multi-step method for preparation of placental membrane scaffolds for treating wounds.
- US20200337904 A1 is also very exhaustive and costly when compared to the present invention, as it involves many stages and different operations such as preparation of dehydrated human amnion or chorion membrane, collagen swelling, blending of oxidized regenerated cellulose (ORC), add plasticizer etc.
- the material is highly processed and do not retain the original properties of intact amnion-chorion membrane.
- the dressing material contains 2 different layers with added collage, ORC, and plasticizers. Also, please note that the synthesis method is completely different in US20200337904 A1 and the present invention.
- D8 Polyhexamethylene Biguanide: Polyurethane Blend Nanofibrous Membranes forWound Infection Control, Polymers 2019, 11, 915; doi:10.3390/polym11050915, 22 May 2019, discloses the use of nano fibrous membranes prepared by blending PHMB and polyurethane to gradually release PHMB for wound infection control.
- the synthesis procedure and working principle of the prior art is completely different from the present invention. This results in a product which is in nanoscale regime.
- the prior art did not disclose any information regarding the use of human amnion-chorion membrane as in the present invention. Hence, kindly consider that our work is inventive in view of the prior art.
- D1 to D4 discloses about development of rigid multilayer wound dressing constructs to be placed inside the boundaries of wounds.
- D5 and D6 uses highly exhaustive steps to process the amnion and chorion membrane into multilayered material. Also, in the works D1 to D6 the amnion and chorion layers are separated and there was no mention of impregnation of PHMB which makes them entirely different from the present invention.
- Reference D7 is a review paper that compares PHMB with other competitive materials.
- Reference D8 is a physicochemical work which discloses the use of nano fibrous membranes. There is no mention about human amnion-chorion membrane in D7 and D8.
- the present invention resulted in a new product (PHMB impregnated intact dAmCh), involves technical advance (impregnation of PHMB), have economic significance (minimal processing, minimal manipulation, easy to use, less medical intervention, bio absorbable and hence savings in disposal), and efficacy (synergetic effect of impregnated PHMB and dAmCh membrane in effective wound healing).
- PHMB impregnated intact dAmCh involves technical advance (impregnation of PHMB), have economic significance (minimal processing, minimal manipulation, easy to use, less medical intervention, bio absorbable and hence savings in disposal), and efficacy (synergetic effect of impregnated PHMB and dAmCh membrane in effective wound healing).
- the therapeutic possibilities in a combination of PHMB and placental membrane allografts has not been explored and is expected to have a cumulative effect in clearing infectious organisms from the wound.
- a placental membrane based wound dressing material essentially consisting of: a polyhexamethylene biguanide impregnated dehydrated amnion-chorion membrane; wherein 0.5-2 % polyhexamethylene is distributed in 1 gm dehydrated amnion- chorion membrane. It is another aspect of the present invention to provide the placental membrane based wound dressing material, wherein 1gm of amnion-chorion membrane comprises of 5 mg of PHMB. It is another aspect of the present invention to provide the placental membrane based wound dressing material, wherein the dehydrated amnion-chorion is derived from human placental layers.
- the antimicrobial agent is PHMB in combination with one or more of Tetracycline, Penicillin, Neomycin, Erythromycin, Clindamycin, Silver, Iodine, Chlorhexidine, Oflaxacin, Ethyl alcohol, Povidine iodine, Framycetin, Mupirocin, Dicloxacillin, Cephalosporins.
- FIG. 1 Illustrates the flow chart of method of preparation of AmchoPlast – PHMB membrane.
- Figure 2 illustrates the flow chart amnion-chorion membrane with 0.5% PHMB membrane – according to an embodiment of the present invention.
- the present invention relates to the field of chronic wound management and healing. More particularly, AmchoPlast-PHMB: augmented antimicrobial activity and functional efficacy for the treatment of wounds.
- the present invention gives a Minimally processed one-layer flexible membrane with intact amnion and chorion membrane having its regenerative properties.
- the wound dressing material of the present invention can be placed over the wound or inside the wound also. Wound healing attributes of placental membrane allograft dehydrated human amnion-chorion (dAmCh) membrane is enhanced by impregnation with the broad-spectrum antimicrobial polymer Polyhexamethylene Biguanide (PHMB).
- the components in the biomaterial have a synergic effect as evidenced by the augmented antimicrobial effect on planktonic culture of microbial species predominating the polyspecies-biofilms of infected recalcitrant wounds.
- PHMB-AmchoPlast as an effective anti-biofilm agent would be established further using an in vitro biofilm model of chronic wound.
- dAmCh retains the structural and biological properties of placental membrane.
- the antimicrobial components and the array of cytokines, chemokines and growth factors facilitate repair and regeneration of infected wounds.
- the method of preparation of wound dressing material involves:
- the placental membrane collected in aseptic conditions and subjected to microbial and infectious disease screening is used for production of the dressing material.
- the membrane with intact amnion and chorion layers is gently washed, dried and incubated for a standardized time in a defined concentration of PHMB solution.
- PHMB concentration requirement in the wound dressing material is 0.5% w/w.
- 0.125 gm of PHMB powder shall be dissolved in 100 ml of sterile water for injection.
- the dehydrated membrane weight is 1 gm, it is required to add 4ml of 0.125% PHMB solution to achieve 0.5% of PHMB concentration in Final product (1 gm of tissue contains 5 mg of PHMB).
- the dried membrane weight is noted, and soaking volume is calculated based on the weight (WEIGHT*4) of 1.25mg/ml PHMB for 4 hours in the shaker incubator at 100 (+/- 10) RPM. After 4 hours incubation the soaked membrane is removed from the container and spread on the Inverse “LC” Delrin block, where amnion is facing downward and chorion facing upward.
- Chorionic layer is thicker compared to the amnion layer.
- the amnion layer is comparatively translucent to the chorionic layer.
- Delrin block placed in Tyvek pouch should be sealed and incubated in Hot air oven at 40 ⁇ 2 °C for 16-24 hours.
- Packaging procedure for subjecting dehydrated membrane to Gamma radiation The dehydrated membrane is packed in Primary Pouch and sealed with nitrogen using a vacuum sealer. Then, primary packaged membrane is kept inside the Pre labelled Secondary pouch and sealed by purging with nitrogen. After dehydration the membrane is cut using laser with membrane sealed in Tyvek pouch to specific dimensions, sealed and sterilized by gamma irradiation 25kGy. The physical and functional characteristics of the product are validated by established protocols.
- Antimicrobial property In vitro assays proving the synergic effect of PHMB and dAmCH.
- the amniotic membrane is part of the inner layer of the placenta, this is a bilayer membrane composed of amnion and chorion.
- the amniotic membrane if a daunting natural biological barrier that separates the fetal and maternal tissues. It is an immune-privileged tissue.
- the use of dehydrated placental membranes in wound healing care has been successful in clinical trials. Nevertheless, bacterial infection of the wound remains as a major concern affecting the wound healing process.
- coating of the dehydrated amnion chorion membrane with antimicrobial compounds could be an effective strategy to overcome this barrier.
- the broad-spectrum antimicrobial Biocide Poly hexamethylene biguanide (PHMB) kills bacteria, fungi, parasites and certain viruses with a high therapeutic index.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention relates to the field of acute and chronic wound management. It particularly relates to intact dehydrated human amnion chorion membrane (dAmCh) impregnated with polyhexamethylene (PHMB) wound dressing material which offers excellent wound healing properties.
Description
A HUMAN AMNION-CHORION BASED WOUND DRESSING MATERIAL AND METHOD THEREOF FIELD OF THE INVENTION The present invention relates to the field of acute and chronic wound management and healing. More particularly, it relates to wound healing attributes of placental membrane allograft, dehydrated human amnion-chorion (dAmCh) membrane impregnated with the broad spectrum antimicrobial polymer, Polyhexamethylene Biguanide (PHMB). BACKGROUND OF THE INVENTION Placenta-derived membranes are widely used as cellular matrices in the treatment of chronic wounds (Hughes et al, 2016), being immunoprivileged they are ideal for allograft therapies. The structural complexity and presence of growth factors, cytokines and remodeling enzymes supports tissue regeneration and healing (Lim and Koob, 2016). Additionally, chorioamniotic membrane is known to have antimicrobial, anti-analgesic and anti-fibrotic properties (Hoang et al, 2014. Johnson et al, 2017). Single layer allografts of amnion membrane (HA) as well as composite amnion-chorion (HACM) grafts are widely marketed and several patents filed in this regard (US20150110850A1;EP2884844AG). Koob et al (2014) reported a five-fold enhanced efficiency in terms of cytokine profile and immunomodulatory effects in the composite graft, Epifix® (MiMedX, GA) as compared to the amnion graft, Aminofix®(MiMedx, GA). There is a differential distribution of ECM macromolecules in the amnion and chorion, the chorionic trophoblast is usually excluded from grafts due to the relative abundance of metalloproteases and other proinflammatory cytokines (Lei et al, 2016). Variation in tissue processing techniques is reported to have significant impact on preserving bioactivity, therefore PURION® processed HA grafts retained more active components in comparison to other similar products (Koob et al, 2014). Preservation procedures such as cryopreservation and dehydration and sterilization by gamma irradiation affect the physical and functional characteristics of grafts (Paolin et al, 2016). Most of the commercially available PM grafts are dehydrated (Ilic et al, 2017), however cryopreservation (eg.Stravix™, Ociris Therapeutics) retains the structural features of the matrix, viability and response to simulated wound environment (Johnson et al, 2017). Characterization of the Chorioamniotic membrane in terms of its structure, and evaluation of its bioactive components in the context of their functional significance have been well defined (Rennert et al,2013.,Koob et al, 2014.,Lei et
al,2016.,McQuilling et al,2018). The antimicrobial property of the membrane was reported by some investigators (Yadav et al, 2017. Palankar et al., 2019). While most of the studies have used viable/cryopreserved composite membranes, evaluation of antimicrobial activity of the dehydrated AmCh membrane or its extracts is important. Antiseptics are commonly used as an adjunctive treatment for chronic wounds. Polyhexamethylene Biguanide (PHMB) is a safe, broad spectrum antimicrobial polymer most commonly and effectively used in controlling polyspecies microbial load in wounds (Sowlati- Hashijin et al, 2020). Wound dressing impregnated with PHMB, such as PHMB-Bacterial Nano Cellulose, Nemipore, Protosan etc., have improved efficacy. Moreover, the loading of the antiseptic to the dressing material is achieved by a simple procedure (EP1473047B1; de Mattos et al,2019). The references D1: US20130289724 A1, D2: US8961617B2, D3: US20120010727A1, and D4: US20120010708A1 discloses about the possible use of an allograft having at least one layer of human amnion and chorion tissues for use as wound cover, allograft in abdominal surgery, allograft in sport injury surgery, and as a replacement cover for muscle sheath, respectively. The cited references are different from the present inventions as (a) the developed product do not contain impregnated PHMB; (b) it is a multilayer, rigid construct which needs assembly of allograft, base sheet, and support layer into wound dressing; (c) it do not have an intact amnion-chorion membrane as they are separated by mechanical stripping; (d) the respective dressing is to be placed inside the boundaries of wound; and (e) it mentions about the application of processed viscous amniotic fluid to surgery site to enhance the healing. D5: IN2456/CHE/2015A discloses a multi-step method for preparation of placental membrane scaffolds for treating wounds. The process in IN2456/CHE/2015A is highly exhaustive and costly when compared to the present invention, as it involves many stages and different operations such as removal of hyaluronic acid and mucopolysaccharides, enzymatic treatment, collagen crosslinking, and freeze drying. The scaffolds are highly processed and do not retain the original properties of intact amnion-chorion membrane. Also, please note that the synthesis method is completely different in IN2456/CHE/2015A and the present invention.
D6: US20200337904 A1 discloses a multi-step method for preparation of dressing including dehydrated placental tissue for wound cleaning. The process in US20200337904 A1 is also very exhaustive and costly when compared to the present invention, as it involves many stages and different operations such as preparation of dehydrated human amnion or chorion membrane, collagen swelling, blending of oxidized regenerated cellulose (ORC), add plasticizer etc. The material is highly processed and do not retain the original properties of intact amnion-chorion membrane. The dressing material contains 2 different layers with added collage, ORC, and plasticizers. Also, please note that the synthesis method is completely different in US20200337904 A1 and the present invention. D7: “Effectiveness of polyhexamethylene biguanide impregnated dressing in wound healing: a systematic review protocol” JBI Database of Systematic Reviews and Implementation Reports, 2016, summarizes the review of work done in PHMB impregnated dressing for wound healing. The review papers dealt exclusively with healing properties of PHMB compared with silver, iodine, standard dressing, regular dressing, and other antimicrobial dressings. Furthermore, it did not disclose any information regarding the use of human amnion- chorion membrane as in the present invention. Hence, kindly consider that our work is inventive in view of the prior art. D8: Polyhexamethylene Biguanide: Polyurethane Blend Nanofibrous Membranes forWound Infection Control, Polymers 2019, 11, 915; doi:10.3390/polym11050915, 22 May 2019, discloses the use of nano fibrous membranes prepared by blending PHMB and polyurethane to gradually release PHMB for wound infection control. The synthesis procedure and working principle of the prior art is completely different from the present invention. This results in a product which is in nanoscale regime. Also, the prior art did not disclose any information regarding the use of human amnion-chorion membrane as in the present invention. Hence, kindly consider that our work is inventive in view of the prior art. In summary, D1 to D4 discloses about development of rigid multilayer wound dressing constructs to be placed inside the boundaries of wounds. D5 and D6 uses highly exhaustive steps to process the amnion and chorion membrane into multilayered material. Also, in the works D1 to D6 the amnion and chorion layers are separated and there was no mention of impregnation of PHMB which makes them entirely different from the present invention. Reference D7 is a review paper that compares PHMB with other competitive materials.
Reference D8 is a physicochemical work which discloses the use of nano fibrous membranes. There is no mention about human amnion-chorion membrane in D7 and D8. The present invention resulted in a new product (PHMB impregnated intact dAmCh), involves technical advance (impregnation of PHMB), have economic significance (minimal processing, minimal manipulation, easy to use, less medical intervention, bio absorbable and hence savings in disposal), and efficacy (synergetic effect of impregnated PHMB and dAmCh membrane in effective wound healing). The therapeutic possibilities in a combination of PHMB and placental membrane allografts has not been explored and is expected to have a cumulative effect in clearing infectious organisms from the wound. OBJECT OF THE INVENTION It is primary object of the present invention to provide a synergistically effective minimally processed, intact dehydrated human amnion chorion membrane (dAmCh) and impregnated PHMB. It is another object of the present invention to provide a wound dressing material which offers excellent wound healing properties. It is another object of the present invention to provide a single layer, ready to use wound cover and its one step application makes it user friendly. It is another object of the present invention to develop product that is bio-absorbable and hence not much medical intervention is required. SUMMARY OF THE INVENTION One or more of the problems of the conventional prior arts may be overcome by various embodiments of the present invention. It is another aspect of the present invention to provide a placental membrane based wound dressing material, essentially consisting of:
a polyhexamethylene biguanide impregnated dehydrated amnion-chorion membrane; wherein 0.5-2 % polyhexamethylene is distributed in 1 gm dehydrated amnion- chorion membrane. It is another aspect of the present invention to provide the placental membrane based wound dressing material, wherein 1gm of amnion-chorion membrane comprises of 5 mg of PHMB. It is another aspect of the present invention to provide the placental membrane based wound dressing material, wherein the dehydrated amnion-chorion is derived from human placental layers. It is another aspect of the present invention to provide the placental membrane based wound dressing material, wherein the PHMB impregnated dehydrated amnion-chorion membrane has augmented antimicrobial activity and functional efficacy for the treatment of chronic wound. It is another aspect of the present invention to provide the placental membrane based wound dressing material, wherein the PHMB is composed of repeating basic biguanidine units connected by hexamethylene hydrocarbon chains, providing a cationic and amphipatic structure. It is another aspect of the present invention to provide the placental membrane based wound dressing material, wherein the antimicrobial agent is PHMB in combination with one or more of Tetracycline, Penicillin, Neomycin, Erythromycin, Clindamycin, Silver, Iodine, Chlorhexidine, Oflaxacin, Ethyl alcohol, Povidine iodine, Framycetin, Mupirocin, Dicloxacillin, Cephalosporins. It is another aspect of the present invention to provide a method of preparation named AGNES technology where placental membrane based wound dressing material, comprising of steps: collection of placental tissue; subjecting the membranes to microbial and infectious disease screening; washing in sterile water and antibiotic solution; cleaning the placental tissue with sterile saline; gentle washing the placental tissue in placental washing solution (2X RBC Lysis solution and 18% NaCl) in 100 rpm shaking incubator for 45-60 minutes;
washing in sterile distilled water in 100 rpm shaking incubator for 10 – 15 minutes; spreading the membrane on delrin block and keeping the membrane in tyvek pouch for drying at 40 ± 2 degree Celsius in hot air oven for 16-24 hours; incorporating 0.5% PHMB in AMCH membrane and drying at 40 ± 2 degree Celsius in hot air oven for 16-24 hours; and slicing the membranes to specific dimensions, sealing and subjecting to sterilization by gamma radiation. It is another aspect of the present invention to provide the method of preparation of placental membrane based wound dressing material, wherein the slicing of membrane is done using laser. BRIEF DESCRIPTION OF DRAWINGS Figure 1 Illustrates the flow chart of method of preparation of AmchoPlast – PHMB membrane. Figure 2 illustrates the flow chart amnion-chorion membrane with 0.5% PHMB membrane – according to an embodiment of the present invention.
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to the field of chronic wound management and healing. More particularly, AmchoPlast-PHMB: augmented antimicrobial activity and functional efficacy for the treatment of wounds. The present invention gives a Minimally processed one-layer flexible membrane with intact amnion and chorion membrane having its regenerative properties. The wound dressing material of the present invention can be placed over the wound or inside the wound also. Wound healing attributes of placental membrane allograft dehydrated human amnion-chorion (dAmCh) membrane is enhanced by impregnation with the broad-spectrum antimicrobial polymer Polyhexamethylene Biguanide (PHMB). The components in the biomaterial have a synergic effect as evidenced by the augmented antimicrobial effect on planktonic culture of microbial species predominating the polyspecies-biofilms of infected recalcitrant wounds. PHMB-AmchoPlast as an effective anti-biofilm agent would be established further using an in vitro biofilm model of chronic wound. dAmCh retains the structural and biological properties of placental membrane. The antimicrobial components and the array of cytokines, chemokines and growth factors facilitate repair and regeneration of infected wounds. However, prolonged infection, high microbial load and the temporal dynamics of the wound microbiome can outcompete the antimicrobial potential of the membrane, further making the environment less conducive for reparative agents (Bowler et al, 2001., Lei et al, 2016., Loesche et al, 2017).This is more apparent with biofilm forming species that are resistant to antimicrobial agents; imbalanced production of proteases also degrades growth factors and cytokines impairing the healing process (Mir et al, 2018) PHMB and dAmCh can have a synergic effect in bringing down microbial load, possibly destabilizing the microbiota in the wound facilitating continuous healing. It is important in a scenario where the wound microbiome can possibly limit the therapeutic potential of the placental membrane. General overview of the present invention: • Dehydrated amnion chorion (dAmCh) with augmented antimicrobial efficiency
• Antiseptic PHMB incorporated in dAmCh
• dAmCh retains its wound healing and regenerative properties
• Polyspecies biofilm forming microbial species, in vitro studies
• Synergic antimicrobial effect of dAmCh-PHMB membrane
• Wound more conducive for the therapeutic active components of dAmCh.
According to the present invention, the method of preparation of wound dressing material involves:
The placental membrane collected in aseptic conditions and subjected to microbial and infectious disease screening is used for production of the dressing material. The membrane with intact amnion and chorion layers is gently washed, dried and incubated for a standardized time in a defined concentration of PHMB solution.
Summarized Procedure:
Clean the placental membrane with Purified water (Milli-Q) / normal saline then clean with Placental washing solution (RBC lysis solution containing 18% NaCl) to remove blood stains/extra layers and dehydrate at 40 ± 2 °C and incorporate amnion chorion membrane with PHMB and again dehydrated at 40 ± 2°C. Dehydrated PHMB allografts are sterilized and packed.
Preparation of PHMB solution:
0.5% PHMB membrane preparation (w/w):
0.5 g of PHMB in 100 ml of water - 0.5%
0.5 g of PHMB in 100 g of tissue weight - 0.5% Therefore 500 mg in 100000 mg of tissue.
PHMB concentration requirement in the wound dressing material is 0.5% w/w.
0.125% working PHMB solution preparation:
0.125 gm of PHMB powder shall be dissolved in 100 ml of sterile water for injection.
For e.g., considering the dehydrated membrane weight is 1 gm, it is required to add 4ml of 0.125% PHMB solution to achieve 0.5% of PHMB concentration in Final product (1 gm of tissue contains 5 mg of PHMB). The dried membrane weight is noted, and soaking volume is calculated based on the weight (WEIGHT*4) of 1.25mg/ml PHMB for 4 hours in the shaker incubator at 100 (+/- 10) RPM. After 4 hours incubation the soaked membrane is removed from the container and spread on the Inverse “LC” Delrin block, where amnion is facing downward and chorion facing upward. Chorionic layer is thicker compared to the amnion layer. The amnion layer is comparatively translucent to the chorionic layer. Delrin block placed in Tyvek pouch should be sealed and incubated in Hot air oven at 40±2 °C for 16-24 hours. Packaging procedure for subjecting dehydrated membrane to Gamma radiation: The dehydrated membrane is packed in Primary Pouch and sealed with nitrogen using a vacuum sealer. Then, primary packaged membrane is kept inside the Pre labelled Secondary pouch and sealed by purging with nitrogen. After dehydration the membrane is cut using laser with membrane sealed in Tyvek pouch to specific dimensions, sealed and sterilized by gamma irradiation 25kGy. The physical and functional characteristics of the product are validated by established protocols. In terms of clarity, thickness, moisture content, tensile strength, total protein content, as well as in the presence of cytokines, growth factors, angiogenic and cell proliferative potential, the product is confirmed to be ideally retaining the known properties of dAmCh membrane. The incorporation of PHMB did not alter any of its inherent qualities. The properties of the Amnion-chorion wound dressing material according to the present invention: Values are as Mean + Standard Deviation (n=8) Tensile strength - 4.62 ± 2.81 (Newton) Moisture content - 9.39 ± 2.80 % Total protein content - 0.98 ± 0.26 mg/cm2 Thickness - 82.83 ± 16.72 µ
Transparency - 83.14 ± 3.13 µ. Antimicrobial property: In vitro assays proving the synergic effect of PHMB and dAmCH. A comparison of the inherent antimicrobial properties of dAmCh (AmchoPlast) and dAmCh- PHMB (AmchoPlast-PHMB) in planktonic culture involving microbial species frequently found in a chronic wound microbiome. The efficiency of AmchoPlast-PHMB would be further established by an in vitro-biofilm model of chronic wound. Synergic effect of antimicrobial components of dAmCh and PHMB in decreasing high microbial load, facilitating the continuation of normal wound healing. The wound environment can be more conducive to the anti-inflammatory and growth promoting effects of dAmCh in case of recalcitrant chronic wounds. The amniotic membrane is part of the inner layer of the placenta, this is a bilayer membrane composed of amnion and chorion. Thus, the amniotic membrane if a formidable natural biological barrier that separates the fetal and maternal tissues. It is an immune-privileged tissue. The use of dehydrated placental membranes in wound healing care has been successful in clinical trials. Nevertheless, bacterial infection of the wound remains as a major concern affecting the wound healing process. Hence, coating of the dehydrated amnion chorion membrane with antimicrobial compounds could be an effective strategy to overcome this barrier. The broad-spectrum antimicrobial Biocide Poly hexamethylene biguanide (PHMB) kills bacteria, fungi, parasites and certain viruses with a high therapeutic index.
Claims
WE CLAIM: 1. A placental membrane based wound dressing material, essentially consisting of: a polyhexamethylene biguanide impregnated dehydrated amnion-chorion membrane, wherein 0.5-2 % polyhexamethylene is distributed in 1 gm dehydrated amnion- chorion membrane. 2. The placental membrane based wound dressing material as claimed in claim 1, wherein 1gm of amnion-chorion membrane comprises of 5 mg of PHMB. 3. The placental membrane based wound dressing material as claimed in claim 1, wherein the dehydrated amnion-chorion is derived from human placental layers. 4. The placental membrane based wound dressing material as claimed in claim 1, wherein the PHMB impregnated dehydrated amnion-chorion membrane has augmented antimicrobial activity and functional efficacy for the treatment of chronic wound. 5. The placental membrane based wound dressing material as claimed in claim 1, wherein the PHMB is composed of repeating basic biguanidine units connected by hexamethylene hydrocarbon chains, providing a cationic and amphipatic structure. 6. The placental membrane based wound dressing material as claimed in claim 1, wherein the antimicrobial agent is PHMB in combination with one or more of Tetracycline, Penicillin, Neomycin, Erythromycin, Clindamycin, Silver, Iodine, Chlorhexidine, Oflaxacin, Ethyl alcohol, Povidine iodine, Framycetin, Mupirocin, Dicloxacillin, Cephalosporins. 7. A method of preparation named AGNES technology where placental membrane based wound dressing material, comprising of steps: collection of placental tissue; subjecting the membranes to microbial and infectious disease screening; washing in sterile water and Antibiotic solution; cleaning the placental tissue with sterile saline; gentle washing the placental tissue in placental washing solution (2X RBC Lysis solution and 18% NaCl) in 100 rpm shaking incubator for 45-60 minutes;
washing in sterile distilled water in 100 rpm shaking incubator for 10 – 15 minutes; spreading the membrane on delrin block and keeping the membrane in tyvek pouch for drying at 40 ± 2 degree Celsius in hot air oven for 16-24 hours; incorporating 0.5% PHMB in AMCH membrane and drying at 40 ± 2 degree Celsius in hot air oven for 16-24 hours; and slicing the membranes to specific dimensions, sealing and subjecting to sterilization by gamma radiation. 8. The method of preparation of placental membrane based wound dressing material as claimed in claim 7, wherein the slicing of membrane is done using laser.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202141037032 | 2021-08-16 | ||
| IN202141037032 | 2021-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023021525A1 true WO2023021525A1 (en) | 2023-02-23 |
Family
ID=85240253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2022/050734 WO2023021525A1 (en) | 2021-08-16 | 2022-08-16 | A human amnion-chorion based wound dressing material and method thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023021525A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024192119A1 (en) * | 2023-03-14 | 2024-09-19 | Direct Biologics, Llc | Wound healing compositions and methods thereof |
| US12213995B2 (en) | 2019-07-18 | 2025-02-04 | Direct Biologics, Llc | Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019126368A1 (en) * | 2017-12-20 | 2019-06-27 | Kci Usa, Inc. | Dressing including dehydrated placental tissue for wound healing |
| WO2019152110A1 (en) * | 2018-01-31 | 2019-08-08 | Kci Usa, Inc. | Antimicrobial composition, dressing, dressing components, and method |
| US20190282732A1 (en) * | 2016-11-02 | 2019-09-19 | Axogen Corporation | Amnion tissue grafts and methods of preparing and using same |
-
2022
- 2022-08-16 WO PCT/IN2022/050734 patent/WO2023021525A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190282732A1 (en) * | 2016-11-02 | 2019-09-19 | Axogen Corporation | Amnion tissue grafts and methods of preparing and using same |
| WO2019126368A1 (en) * | 2017-12-20 | 2019-06-27 | Kci Usa, Inc. | Dressing including dehydrated placental tissue for wound healing |
| WO2019152110A1 (en) * | 2018-01-31 | 2019-08-08 | Kci Usa, Inc. | Antimicrobial composition, dressing, dressing components, and method |
Non-Patent Citations (1)
| Title |
|---|
| TAN MARY, MORDIFFI SITI ZUBAIDAH, LANG DORA: "Effectiveness of polyhexamethylene biguanide impregnated dressing in wound healing : a systematic review protocol", JBI LIBRARY OF SYSTEMATIC REVIEWS, WOLTERS KLUWER - HEALTH LEARNING, RESEARCH & PRACTICE, US, vol. 14, no. 7, 1 July 2016 (2016-07-01), US , pages 76 - 83, XP093038655, ISSN: 2202-4433, DOI: 10.11124/JBISRIR-2016-002991 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12213995B2 (en) | 2019-07-18 | 2025-02-04 | Direct Biologics, Llc | Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use |
| WO2024192119A1 (en) * | 2023-03-14 | 2024-09-19 | Direct Biologics, Llc | Wound healing compositions and methods thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10576037B2 (en) | Compositions comprising placental collagen for use in wound healing | |
| WO2023021525A1 (en) | A human amnion-chorion based wound dressing material and method thereof | |
| RU2748184C2 (en) | Composition for wound dressings | |
| CA2524184C (en) | Microbial cellulose wound dressing comprising phmb | |
| EP3842078A1 (en) | Sheet tissue products | |
| EP1356831B1 (en) | Microbial cellulose wound dressing for treating chronic wounds | |
| NZ206488A (en) | Liquid-loaded medical pad with microbially-produced cellulose | |
| WO2007048099A2 (en) | Antimicrobial collagenous constructs | |
| AU2002309898A1 (en) | EB matrix production from fetal tissues and its use for tissue repair | |
| US9510937B2 (en) | Device for tendon and ligament treatment | |
| CN115845141B (en) | Preparation method and application of dry amniotic membrane | |
| US20040142019A1 (en) | Microbial-derived cellulose amorphous hydrogel wound dressing | |
| Kramer et al. | Polypragmasia in the therapy of infected wounds–conclusions drawn from the perspectives of low temperature plasma technology for plasma wound therapy | |
| RU2437681C1 (en) | Wound covering with therapeutic action | |
| EP1438975B1 (en) | Microbial-derived cellulose amorphous hydrogel wound dressing | |
| CN105169464B (en) | A kind of natural honey wound dressing and preparation method and application | |
| CA2484953C (en) | Microbial cellulose wound dressing for treating chronic wounds | |
| KR100333317B1 (en) | Method for preparation of hydrogels dressings by using radiation | |
| Paleczny et al. | Modifications of bacterial cellulose in wound care | |
| TW200817055A (en) | Disinfection method for biomaterial | |
| NL2033318B1 (en) | Sterile human placental allografts and methods of making thereof | |
| WO2004064880A1 (en) | Microbial-derived cellulose amorphous hydrogel wound dressing | |
| KR100372560B1 (en) | Charcoal filled hydrogels dressings and process for preparing thereof by irradiation | |
| CN115068661B (en) | Calcium alginate composite porous biological matrix dressing, and preparation method and application thereof | |
| RU2712701C1 (en) | Implant for bone tissue replacement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22858038 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22858038 Country of ref document: EP Kind code of ref document: A1 |